市场调查报告书
商品编码
1433401
全球瞳孔计市场 2023-2030Global Pupillometer Market 2023-2030 |
预计在预测期内(2023-2030 年),全球瞳孔计市场将以 6.9% 的CAGR成长。该市场的成长归因于全球医疗保健需求的不断增长。在医疗保健领域,对可靠、高效的诊断工具的需求不断增长,特别是在眼科、神经病学和重症监护等领域。瞳孔计对于诊断神经系统疾病、脑外伤和监测重症监护患者至关重要。例如,2020 年 8 月,Topcon Healthcare 推出了新型 Aladdin-M 仪器。 Aladdin-M 整合了角膜地形图、瞳孔测量和光学生物测量,可可靠地评估角膜曲率、瞳孔动态和眼轴长度指标。
全球瞳孔计市场按类型、应用和最终用户进行细分。根据类型,市场分为数位和视讯。根据应用,市场细分为眼科、神经科、肿瘤科等。此外,根据最终用户,市场细分为医院、眼科诊所等。眼科子类别预计将占据应用领域的很大一部分市场份额。这种增长可归因于对屈光手术和白内障手术中精确测量和精心规划的要求所驱动的眼科手术的精确性需求。这导致人们对 SeeNa 等系统越来越感兴趣,这些系统可以帮助外科医生实现最佳的手术结果。例如,2023年10月,博士伦公司推出了针对屈光性白内障患者的SeeNa光学生物测量和地形图系统。
在这些应用中,神经学细分市场预计将在全球瞳孔计市场中占据相当大的份额。节段性生长归因于神经系统疾病的增加。神经系统疾病和创伤性脑损伤的盛行率不断上升,需要利用瞳孔计等精确诊断设备来进行及时检查和治疗。例如,2021 年2 月,NeurOptics 推出了瞳孔测量教育研讨会平台,其中包括一系列以产品和临床为重点的演示,展示了瞳孔测量和神经瞳孔指数(NPi) 在评估和筛检高风险患者中的重要作用的神经损伤。
全球瞳孔计市场根据地理位置进一步细分,包括北美(美国和加拿大)、欧洲(英国、义大利、西班牙、德国、法国和欧洲其他地区)、亚太地区(印度、中国、日本、韩国、亚洲其他地区)以及世界其他地区(中东和非洲以及拉丁美洲)。其中,亚太地区预计将在全球市场中占据显着份额,因为该地区的瞳孔计透过一系列网站和供应商的可用性不断增加,预计将推动市场扩张。
在所有地区中,北美地区预计在预测期内将以相当大的CAGR成长。区域增长归因于该地区不断增长的临床需求。揭示放射学指标与神经系统疾病之间潜在关联的资料强调了精确诊断方法的重要性。瞳孔计可以独立量化瞳孔反应性,在 IPH 和缺血性中风等疾病的神经学检查中越来越有用。根据美国国立卫生研究院 (gov.) 2022 年 12 月的研究,在 74 张 CT 影像的 53 名患者中,49.1% 为女性,中位年龄为 67 岁。与缺血性中风患者相比,IPH 患者的 MLS-SP 和 PGS 较高,测量值分别为 6.2 毫米与 4.0 毫米以及 5.6 毫米与 3.4 毫米。研究发现瞳孔反应性和放射学位移标记之间没有显着关联,但在 IPH 和缺血性中风队列中发现 MLS-SP 和 Diff NPi 之间存在潜在关係。这表明中线移位和不对称瞳孔反应性之间的关联在 IPH 和缺血性中风之间有所不同,强调需要进行额外的前瞻性研究。
服务于瞳孔计市场的主要公司包括HAMAMATSU Group、HEINE Optotechnik GmbH & Co. KG、Johnson & Johnson Vision Care, Inc.、KARL STORZ、Konan Medical USA Inc.等。市场参与者透过各种策略(包括併购、合作、合作、融资和新产品发布),为市场成长做出了巨大贡献,以保持市场竞争力。例如,2021年7月,NeurOptics在美国推出了NPi-300瞳孔计。 NPi-300 瞳孔计是一款用于成人和儿童患者神经系统检查的多功能工具,涵盖广泛的诊断,例如创伤性脑损伤、中风、癫痫和其他医疗状况。
Global Pupillometer Market Size, Share & Trends Analysis Report by Type (Digital, and Video), by Application (Ophthalmology, Neurology, Oncology, and Others) and by End User (Hospitals, Eye Clinics, and Others), Forecast Period (2023-2030)
The global pupillometer market is anticipated to grow at a CAGR of 6.9% during the forecast period (2023-2030). The market's growth is attributed to the growing demand in healthcare across the globe. In healthcare, it contains an increasing demand for reliable and efficient diagnostic tools, particularly in sectors such as ophthalmology, neurology, and critical care. The pupillometers are essential in diagnosing neurological diseases, brain traumas, and monitoring patients in critical care situations. For instance, in Augut 2020, Topcon Healthcare launched its new Aladdin-M instrument. Aladdin-M integrates corneal topography, pupillometry, and optical biometry to assess corneal curvature, pupil dynamics, and axial length metrics reliably.
The global pupillometer market is segmented on the type, application, and end user. Based on the type, the market is sub-segmented into digital, and video. Based on the application, the market is sub-segmented into ophthalmology, neurology, oncology, and others. Furthermore, on the basis of end user, the market is sub-segmented into hospitals, eye clinics, and others. The ophthalmology subcategory is expected to capture a significant portion of the market share within the application segment. The growth can be attributed to the demand for precision in eye surgeries is driven by the requirement for accurate measurements and meticulous planning in refractive surgeries and cataract procedures. This has led to an increased interest in systems such as, SeeNa, that aid surgeons in achieving the optimal surgical outcomes possible. For instance, in October 2023, Bausch + Lomb Corp. launched the SeeNa optical biometry and topography system for refractive cataract patients.
Among the application, the neurology sub-segment is expected to hold a considerable share of the global Pupillometer market. The segmental growth is attributed to the increasing neurological disorders. The rising prevalence of neurological conditions and traumatic brain injuries needs for the utilization of precise diagnostic equipment such as pupillometers to perform prompt examinations and therapies. For instane, in February 2021, NeurOptics launched Pupillometry Education Symposiums platform, that includes a series of both product and clinical-focused presentations that demonstrate the essential role pupillometry and the neurological pupil index (NPi) play in the assessment and screening of patients at risk of neurological injury.
The global pupillometer market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, Asia-Pacific is anticipated to hold a prominent share of the market across the globe, owing to the increasing availability of pupillometers in the region via a range of websites and vendors is projected to drive market expansion.
Among all regions, the North America regions is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to the increasing clinical demand across the region. The data revealing potential associations between radiographic indicators and neurological disorders underscore the importance of precise diagnosis methods. Pupillometers, that can independently quantify pupil responsiveness, have been increasingly useful in neurological examinations for disorders such as IPH and ischemic stroke. According to the National Institute of health (gov.) in December 2022, as per the study among the 53 patients with 74 CT images, 49.1% were female, with a median age of 67 years. The patients with IPH showed greater MLS-SP and PGS compared to patients with ischemic stroke, with measurements of 6.2 mm versus 4.0 mm and 5.6 mm versus 3.4 mm, respectively. The study found no significant association between pupil reactivity and radiographic shift markers, but potential relationships were found between MLS-SP and Diff NPi in the IPH and ischemic stroke cohorts. This suggests that the connection between midline shift and asymmetric pupil reactivity varies between IPH and ischemic stroke, emphasizing the need for additional prospective research.
The major companies serving the pupillometer market includes HAMAMATSU Group, HEINE Optotechnik GmbH & Co. KG, Johnson & Johnson Vision Care, Inc., KARL STORZ, Konan Medical USA Inc. and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in July 2021,NeurOptics, launched NPi-300 Pupillometer in the US. The NPi-300 Pupillometer is a versatile tool for neurological examination in both adults and pediatric patients, covering a wide range of diagnoses such as traumatic brain injury, stroke, seizure, and other medical conditions.